all.Love
Hi Donald,
As always, big thanks for nice work on putting together coherent and very informative Q & A form Astral management. After going through I have following observations.
)- Apparently Astral has exclusivity for 3 products except for the flowguard. How long is this exclusivity validfor each of the products? Is it long enough to cover for the whole patented period? Is there any contractual arrangement on the same?
)- Is there any royalty payment/revenue sharing arrangement with lubrizol? Does this arrangement have timeline for re-negotiation or is the royalty (% or absolute amount)fixed for the period of engagement?
)- Kaneka is a credible competitor that combined with brand equity/reach of supreme can become a strong competitor for Astral.
)- Another threat that I see is the spoiled relationship with Lubrizol. Currently, everything is hunky-dowry. However what happens if the relationship turns sour? Does company have any risk-mitigation to this threat. I see this as one ofthe major threats because Astral derives significant strength from their relationship with Lubrizol andis a key differentiator. Without relationship with Lubrizol, it is a commodity market out there for CPVC segment.
With respect to allocation, let me pose a question to you why would one prefer Astral over Amararaja? Here are few points
)- Industrial and automotive battery market size is of the tune of 20,000 crores + and has potential to grow expoentially as automobile sales increases the market size widens. Moreover for all newly sold automobiles, there needs to be replacement demand every 3-4 years. This inherent characteristic can make the market size far larger than a product having life cycle of 15-20 years.
)- Astral is still building brand and reach while ARBL has over years done so which helps it gain pricing power. It has consistently maintend 25% ROE for last 5 years while Astral has though increased its ROE, further improvement is unlikely unless asset turns or debt increases. (as management has guided for 12-14% operating margin hence NPM may also settle down around current levels)
)- Global MNC (jhonsons control)has taken 26% equity which more closely ties it up with ARBL and on a longer term basis. For Astral the ties with Lubrizol is less strategic and more prone to break up. Additionally, global MNC being on board may be useful in maitaining corporate governance standards.
)- ARBL and Astral both can grow at 20+% in next 5 years (in my considered opinion)
)- Astral is available at 15 times TTM P/E while ARBL is available at 12.5 times P/E. For ARBL NPM and Asset turns are higher. Moreove inspite of lower debt, its ROE is better than that of Astral.
Eventhough, I toosee good upside in Astral even from current levels, I feel ARBL can be a very strong challenge to Astral in terms of garnering the largest share of capital allocation for a long term portfolio.
Will be glad to know your thoughts.
Best Regards
Dhwanil Desai